{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Woyach JA"],"pubmed_abstract":["<h4>Purpose</h4>Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BTKi. We report results, to our knowledge, from the first randomized head-to-head comparison of pirtobrutinib versus ibrutinib in BTKi-naïve CLL/SLL in both treatment-naïve (TN) patients and patients with relapsed/refractory (R/R) disease.<h4>Patients and methods</h4>Patients (N = 662) were randomly assigned 1:1 to receive pirtobrutinib or ibrutinib. All patients were BTKi-naïve. Primary end points were overall response rate (ORR) by independent review committee (IRC) among all randomly assigned patients (intention to treat [ITT]) and in patients wi"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["JCO2502477"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904240"],"repository":["biostudies-literature"],"pubmed_title":["Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma."],"pmcid":["PMC12904240"],"pubmed_authors":["Agajanian R","Yi S","Eom KS","Woyach JA","Ozcan M","Qiu L","Berkovits A","Bao K","Bian Y","Hill M","Bhandari NR","Leow CC","Coombs CC","Panovska A","Wrobel T","Lewis KL","De Batista Ribeiro SR","Grosicki S","Czyz J","Capra M","Laribi K","Ruppert AS","Cramer P","Jurczak W","Jacobasch L","Lepretre S","Wierda WG","Baker R"],"additional_accession":[]},"is_claimable":false,"name":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.","description":"<h4>Purpose</h4>Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BTKi. We report results, to our knowledge, from the first randomized head-to-head comparison of pirtobrutinib versus ibrutinib in BTKi-naïve CLL/SLL in both treatment-naïve (TN) patients and patients with relapsed/refractory (R/R) disease.<h4>Patients and methods</h4>Patients (N = 662) were randomly assigned 1:1 to receive pirtobrutinib or ibrutinib. All patients were BTKi-naïve. Primary end points were overall response rate (ORR) by independent review committee (IRC) among all randomly assigned patients (intention to treat [ITT]) and in patients wi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T22:02:26.777Z","creation":"2026-07-09T13:09:31.896Z"},"accession":"S-EPMC12904240","cross_references":{"pubmed":["41353787"],"doi":["10.1200/JCO-25-02477"]}}